{"Clinical Trial ID": "NCT00146172", "Intervention": ["INTERVENTION 1:", "Neratinib 40 mg", "Neratinb 40 mg qd", "INTERVENTION 2:", "Neratinib 80 mg", "Neratinib 80 mg qd"], "Eligibility": ["Incorporation criteria:", "Her2/neu or Her1/EGFR positive cancer", "The Eastern Cooperative Oncology Group (ECOG) achieved a yield of 0 to 2", "A measurable disease as defined by the criteria for assessing response in solid tumours (RECIST)", "- Exclusion criteria:", "Prior treatment with anthracyclines with a cumulative dose of doxorubicin or equivalent of more than 300 mg/m^2", "Patients with significant cardiac risk factors", "Metastasis of the active central nervous system"], "Results": ["Performance measures:", "Dose Limiting Toxicity (DLT)", "The DLT is defined as any Grade 3 neratinib-related adverse reaction or Grade 4 adverse reaction (AR) in accordance with the National Cancer Institute (NCI) Common Terminology Criteria (CTC) for Version 3.0 AEs.", "Time: from first dose to day 14", "Results 1:", "Title of the arm/group: Neratinib 40 mg", "Description of the arm/group: Neratinb 40 mg qd", "Total number of participants analysed: 3", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%", "Results 2:", "Title of the arm/group: Neratinib 80 mg", "Description of the arm/group: Neratinib 80 mg qd", "Total number of participants analysed: 4", "Type of measure: Number of participants", "Unit of measure: Participants 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/3 (100.00 per cent)", "Anemia 1/3 (33.33%)", "- Cardiorespiratory arrest 0/3 (0.00 %)", "Tachycardia 1/3 (33.33%)", "- Papilloedema 0/3 (0.00 %)", "Photophobia 0/3 (0.00 %)", "- Glass haemorrhage 0/3 (0.00 %)", "- Abdominal distension 0/3 (0.00 %)", "Abdominal pain 0/3 (0.00 %)", "Ascites 0/3 (0.00 %)", "Diarrhoea 0/3 (0.00 %)", "- Nausea 0/3 (0.00 %)", "Small intestinal obstruction 0/3 (0.00 %)", "Adverse Events 2:", "Total: 1/4 (25.0%)", "Anemia 0/4 (0.00 %)", "- Cardiorespiratory arrest 0/4 (0.00 %)", "Tachycardia 0/4 (0.00 %)", "- Papilloedema 0/4 (0.00 %)", "Photophobia 0/4 (0.00 %)", "- Glass haemorrhage 0/4 (0.00 %)", "- Abdominal distension 0/4 (0.00 %)", "Abdominal pain 0/4 (0.00 %)", "Ascites 0/4 (0.00 %)", "Diarrhoea 0/4 (0.00 %)", "- Nausea 0/4 (0.00 %)", "Small intestinal obstruction 0/4 (0.00 %)"]}